Free beta — full access, free until October 2026. No card, no auto-charge — paid plans are opt-in when they launch.
Amphastar Pharmaceuticals, Inc. (AMPH) Financials & SEC Data · SECfinAPI
Company
Amphastar Pharmaceuticals, Inc. (AMPH)
Standardized SEC financial data for Amphastar Pharmaceuticals, Inc. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001297184 · NASDAQ · Pharmaceutical Preparations.
Income statement
USD
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
$349.8M
$437.8M
$499.0M
$644.4M
$732.0M
$719.9M
Cost of revenue
$206.5M
$238.0M
$250.1M
$293.3M
$358.1M
$363.8M
Gross profit
$143.3M
$199.7M
$248.9M
$351.1M
$373.9M
$356.1M
R&D expense
$67.2M
$60.9M
$74.8M
$73.7M
$73.9M
$85.8M
SG&A expense
$50.4M
$51.4M
$45.1M
$51.5M
$56.7M
$85.9M
Operating income
$11.0M
$69.9M
$107.5M
$197.0M
$205.4M
$140.4M
EBITDA
$20.0M
$80.1M
$120.1M
$222.7M
—
—
Interest expense
$2.2M
$2.1M
$3.0M
$27.2M
$26.8M
$23.2M
Pretax income
$4.6M
$84.1M
$116.0M
$171.4M
$189.8M
$123.6M
Income tax
$3.5M
$20.6M
$23.5M
$31.8M
$29.7M
$25.5M
Net income
$1.4M
$62.1M
$91.4M
$137.5M
$159.5M
$98.1M
EPS (diluted)
$0.03
$1.25
$1.74
$2.60
$3.06
$2.03
Standardized from Amphastar Pharmaceuticals, Inc.'s SEC filings — per-share figures split-adjusted. Full history via the API.